|Referral date||01 November 2011|
Scoped within Batch 19
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|7 November 2011||
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of bevacizumab in combination with chemotherapy for the second line treatment of human epidermal growth factor 2 (HER2) negative metastatic breast cancer as part of our 27th work programme.
The Institute has now been informed by the manufacturer that it has decided not to apply for a centralised marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance